Early-stage positive clinical trial results contribute incremental value to anxious shareholders of biotech companies by validating drugs in their pipelines. These gains are especially magnified when the trials are designed to deal with difficult to treat diseases such as lung cancer or human papillomavirus (HPV), in which there are vast needs for treatment. Earlier this month, shareholders of Clovis Oncology (NASDAQ:CLVS) saw their holdings double in a single day when the company reported strong safety data at the 2013 American Society of Clinical Oncology (OTC:ASCO) meeting. This surge in Clovis's price had me wondering if Inovio (NYSEMKT:INO) longs would share the same success with the company's upcoming catalyst that resembles similar features to those...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|